2,009 results on '"Lichtenstein, Gary R"'
Search Results
2. Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies
3. Cardiovascular Safety of Ozanimod in Patients With Ulcerative Colitis: True North and Open-Label Extension Analyses
4. Impact of Concomitant Corticosteroids on Tofacitinib Induction Efficacy and Infection Rates in Ulcerative Colitis
5. Medical Treatment of Perianal Crohn Disease
6. New Non-anti-TNF-α Biological Therapies for the Treatment of Inflammatory Bowel Disease
7. Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study
8. Novel Therapies for Inflammatory Bowel Disease
9. Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies
10. Exposure to Intravenous Opioids Is Associated With Future Exposure to Opioids in Hospitalized Patients With Inflammatory Bowel Diseases
11. Lifetime Economic Burden of Crohn’s Disease and Ulcerative Colitis by Age at Diagnosis
12. Corticosteroid-Free Remission Through 3 Years of Upadacitinib Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Data From the Phase 3 Long-Term Extension Study U-ACTIVATE.
13. Efficacy, Safety and Immunogenicity of Subcutaneous Infliximab (CT-P13 SC) Monotherapy vs Combination Therapy With Immunosuppressants -- Post Hoc Analysis of LIBERTY-CD and LIBERTY-UC Studies.
14. Precision Medicine: Predicting Disease Course in Patients with Inflammatory Bowel Disease
15. Cancer Risks and Screening with Current and Emerging Drug Therapies in Inflammatory Bowel Diseases
16. Superiority Complex: Do Teaching Hospitals Provide Inferior Care for IBD Patients?
17. Evidence-Based Approach to Chronic Antibiotic Refractory Pouchitis: A Review
18. Highlights in Ulcerative Colitis From Digestive Disease Week 2024.
19. Systematic review: effectiveness and safety of switching between originator infliximab and biosimilar infliximab in patients with inflammatory bowel disease.
20. Evolving Considerations for Thiopurine Therapy for Inflammatory Bowel Diseases—A Clinical Practice Update: Commentary
21. Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study
22. Meeting Report: AGA Biosimilars Roundtable
23. Tofacitinib Treatment Safety in Moderate to Severe Ulcerative Colitis: Comparison of Observational Population Cohort Data From the IBM MarketScan® Administrative Claims Database With Tofacitinib Trial Data
24. Going Third Class: Treatment of Steroid-Dependent Ulcerative Colitis
25. The use of chromoendoscopy for surveillance of inflammatory bowel disease
26. Tricks of the Trade: Treating Your Patient with Moderate-to-Severe IBD
27. New Non-anti-TNF-α Biological Therapies for the Treatment of Inflammatory Bowel Disease
28. Medical Treatment of Perianal Crohn’s Disease Fistulae
29. Biologic Therapy for Crohn’s Disease: Infliximab
30. S844 Early Symptomatic Improvement With Guselkumab Induction Treatment in Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 QUASAR Induction Study
31. S903 Cumulative Response to Guselkumab Through Week 24 of Induction in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 QUASAR Induction Study
32. S1060 Guselkumab Improves Health-Related Quality of Life in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the QUASAR Phase 3 Induction Study
33. S907 Guselkumab Improves Abdominal Pain and Bowel Urgency Symptoms in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 QUASAR Induction Study
34. Optimizing the quality of endoscopy in inflammatory bowel disease: focus on surveillance and management of colorectal dysplasia using interactive image- and video-based teaching
35. The TREAT Registry: Evolution of Knowledge From 1999 to 2017: Lessons Learned
36. Contrast and Comparison of Mesalamine Derivatives in the Treatment of Ulcerative Colitis
37. The Role of Diet and Nutrition in Ulcerative Colitis
38. The History of Medical Therapy of Ulcerative Colitis
39. Novel Biologics for the Treatment of Ulcerative Colitis
40. Cyclosporine for Ulcerative Colitis
41. Improved Hemoglobin Response with Ferric Carboxymaltose in Patients with Gastrointestinal-Related Iron-Deficiency Anemia Versus Oral Iron
42. Pregnancy Outcomes Reported During the 13-Year TREAT Registry: A Descriptive Report
43. Biosimilars in the Treatment of Inflammatory Bowel Disease: Supporting Evidence in 2017
44. 127 - Inflammatory Bowel Disease
45. 'Do I Really Have to Have Another Colonoscopy or Another CT Scan?': Appropriate Disease Monitoring of Newly Diagnosed and Established Inflammatory Bowel Disease
46. The Evaluation, Diagnosis, and Treatment of Inflammatory Bowel Diseases over the Past 100 Years: A Brief Review
47. Endoscopic Diagnosis and Staging of Inflammatory Bowel Disease
48. Contributors
49. Hospitalization Outcomes for Inflammatory Bowel Disease in Teaching vs Nonteaching Hospitals
50. A User-Friendly Prediction Tool to Identify Colectomy Risk in Patients With Ulcerative Colitis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.